Instil Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Instil Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, equals 23% of its market value (net debt). Lower than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-4.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-98.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 83% of Healthcare companies in United States.
Cash Cushion Ratio
−23%Debt, after subtracting cash, equals 23% of its market value (net debt).
Lower than 86% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Instil Bio, Inc. made a loss over the last year. Instil Bio, Inc. owes $0.46 for every $1 it owns. Instil Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossInstil Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.37The share price is 0.37 times Instil Bio, Inc.'s book value per share, lower than 94% of Healthcare companies in United States.
Market cap
$40 MThe total market value of all of Instil Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 76% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$107 MWhat Instil Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$15.83Net worth divided by the number of shares. The share price of $5.84 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-25.3%Instil Bio, Inc. lost 25.3% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
Owes vs Owns
0.46×Instil Bio, Inc. owes $0.46 for every $1 it owns (low), higher than 52% of Healthcare companies in United States.
Dividend yield
NoneInstil Bio, Inc. does not currently pay a dividend.
Profit growth
LossInstil Bio, Inc. made a loss in each of the last two years.
Interest cover
Not coveredInstil Bio, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtInstil Bio, Inc. had $9 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Instil Bio, Inc.: $40 M ÷ $107 M (30 Jun 2026) = 0.4.
What is Instil Bio, Inc.'s return on equity?
Instil Bio, Inc. lost 25.3% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
How much does Instil Bio, Inc. owe compared with what it owns?
Instil Bio, Inc. owes $0.46 for every $1 it owns (low), higher than 52% of Healthcare companies in United States.
Does Instil Bio, Inc. pay a dividend?
No. Instil Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.